1 also known as inducible nitric-oxide synthase), a member of the NOS protein family, defends against microbial infection but may contribute to inflammation and tissue injury when overexpressed (1) . NOS-2 is inducible by lipopolysaccharide (LPS) and a myriad pro-inflammatory cytokines (2) . Transcriptional activation of NOS-2 by these stimuli has been extensively characterized in murine RAW 264.7 macrophages. LPS combined with interferon-␥ (IFN-␥) was reported to activate NOS-2 promoter synergistically. Promoter analysis reveals that two clusters of enhancers located at Ϫ54 to Ϫ236 and Ϫ731 to Ϫ962 of NOS-2 promoter region are essential for the sustained expression of NOS-2 in response to LPSϩIFN-␥ stimulation (3, 4) . The binding of NFB and interferon regulatory factor-1 to the enhancer elements of these two regions are indispensable for NOS-2 transcription (5, 6) . It has been recently reported (7, 8 ) that a CAAT/enhancer-binding protein (C/EBP) element situated at Ϫ142 to Ϫ150 is also involved in NOS-2 expression, but the exact transactivators that bind to this site have not been characterized. COX-2 is also inducible in this murine macrophage by diverse pro-inflammatory mediators. Its induction by these stimuli is typical of an immediately early gene with a rapid and transient time course. Several regulatory elements on murine COX-2 promoter including a cyclic AMP response element, two C/EBP sites, and a single NFB site have been shown to be involved in COX-2 promoter activation (9, 10) . The C/EBP sites have been demonstrated to be required for COX-2 expression in murine cells induced by diverse stimuli including LPS (10 -12) . However, the binding of C/EBP␤ to these two sites have not been fully characterized. Results from our laboratory demonstrate that C/EBP␤ binding to the C/EBP site in human COX-2 promoter is required for COX-2 transcriptional activation by pro-inflammatory mediators such as phorbol 12-myristate 13-acetate and interleukin-1␤ (13) . Aspirin and sodium salicylate at pharmacological concentrations suppress COX-2 transcription by blocking the binding of C/EBP␤ (13, 14) . The effect of salicylate on NOS-2 expression is controversial. Although several reports have shown that salicylate suppresses NOS-2 expression at suprapharmacological concentrations (Ͼ5 mM) by reducing NFB binding (15, 16) , to our knowledge, there is no report on NOS-2 expression influenced by pharmacological concentrations of salicylate. Because NOS-2 and COX-2 expressions are concurrently induced by LPSϩIFN-␥ in RAW 264.7 cells, we used this cell line as a model to test the hypothesis that salicylate at pharmacological concentrations (10 Ϫ4 to 10 Ϫ6 M) inhibits NOS-2 and COX-2 expressions stimulated by LPSϩIFN-␥ by blocking a common C/EBP␤-dependent transcriptional pathway. The results show that salicylate suppressed NOS-2 and COX-2 protein levels and promoter activities by blocking the binding of C/EBP␤ to its respective C/EBP elements on NOS-2 and COX-2 promoters. Our results further show that NOS-2 promoter activity stimulated by LPSϩIFN-␥ for 4 h required C/EBP␤ binding, and at this time period of stimulation, salicylate was effective in suppressing C/EBP␤ binding, thereby reducing the extent of NOS-2 expression. In-terestingly, C/EBP␤ binding was no longer required for NOS-2 expression, and salicylate was incapable of inhibiting NOS-2 promoter activity stimulated by LPSϩIFN-␥ for 24 h.
EXPERIMENTAL PROCEDURES
Cell Culture-RAW 264.7 mouse macrophages (ATCC) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (Sigma), 100 units/ml penicillin, and 100 g/ml streptomycin (Invitrogen). For all experiments, medium was removed, and cells were washed and incubated in serum-free medium for 24 h before stimulation with 2 g/ml LPS (Escherichia coli serotype 0111:B4, Sigma), 40 units/ml IFN-␥ (Roche Molecular Biochemicals), or LPSϩIFN-␥ for indicated time periods.
Transfection and Promoter Activity-A wild-type murine 1.63-kilobase NOS-2 promoter/enhancer fragment (Ϫ1486/ϩ145), its C/EBP site (Ϫ150/Ϫ142) mutant with the substitution of TGATGTAA for GTCGT-GGC, and a 0.9-kilobase COX-2 promoter/enhancer fragment (Ϫ891/ ϩ9) were cloned into pGL3 basic luciferase expression vectors. RAW 264.7 cells at ϳ60% confluence were transfected with the luciferase expression construct according to a procedure described previously (14) . A mixture of 15 g of Lipofectin (Invitrogen) and 4 g of DNA was added to cells and incubated in serum-free medium for 6 h. The medium was replaced with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum for 18 h. Cells were washed with serum-free medium, growth-arrested for 24 h, and stimulated with LPS and IFN-␥ for an indicated period of time. Cells were harvested using Promega lysis buffer, and luciferase activity was measured on a Turner TD-20/20 luminometer. On the same cell lysate, total protein assay was performed.
Western Blot-Western blot analysis was performed as described previously (13) . Cells were washed with cold phosphate-buffered saline containing 0.1 mM phenylmethylsulfonyl fluoride, harvested, and spun down at 3000 rpm for 5 min. Cell pellet was dissolved in solubilizing buffer (1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl 2 , 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 50 mM NaF, 1 mM Na 3 VO 4 , 0.06 mg/ml aprotinin). Cell pellet was then spun down at 10,000 rpm for 15 min. Supernatant was collected, and its protein concentration was determined. For sodium dodecylsulfate-polyacrylamide gel electrophoresis, each lane was loaded with 20 g of protein.
The gel was electrophoretically transferred, and proteins were identified by specific antibodies: anti-NOS-2 antibody (Upstate Biotechnology, Lake Placid, NY), anti-COX-2 antibody (Cayman, Ann Arbor, MI), anti-actin antibody (Oncogene, Boston, MA), and anti-C/EBP␤ (Santa Cruz Biotechnology, Santa Cruz, CA). The protein bands were visualized by enhanced chemiluminescence system (Pierce, Rockford, IL).
Protein-DNA Binding Assay-The binding of nuclear extract proteins to the DNA sequence was performed by a newly developed method using streptavidin-conjugated agarose beads to bind biotinylated DNA probe (17) . Nuclear extracts were prepared from RAW 264.7 cells by a method described previously (17) . 400 g of nuclear extract proteins in 400 l of phosphate-buffered saline buffer containing multiple protease inhibitors (1 mM Na 3 VO 4 , 10 mM NaF, 25 mM ␤-glycerophosphate, 0.1 mM phenylmethylsulfonyl fluoride, 0.06 mg/ml aprotinin, 1 g/ml leupeptin, 0.5 mM dithiothreitol) were incubated with a mixture of 4 g of double-stranded biotinylated oligonucleotides containing murine NOS-2 promoter C/EBP sequence at Ϫ150 to Ϫ142 (underlined in 5Ј-CACAGAGTGATGTAATCAAGCA-3Ј) or COX-2 C/EBP sequence at Ϫ138 to Ϫ130 (5Ј-GGTTCTTGCGCAACTCACT-3Ј) (Integrated DNA Technologies, Coralville, IA) and 40 l of 4% beaded-agarose conjugated with streptavidin (Sigma) for 2 h on a rocking platform at room temperature. The beads were collected by centrifugation at 3000 rpm for 1 min, washed three times with phosphate-buffered saline buffer containing multiple inhibitors, and resuspended in 40 l of Laemmli sample buffer. Nuclear proteins bound to the beads were dissociated by incubation in water bath at 95°C for 5 min and applied to Western blot analysis.
Inhibitors of Signaling Pathways-PD98059, an inhibitor of MEK1/2; LY294002, an inhibitor of phosphatidylinositol-3 kinase (PI3K); SB203580, an inhibitor of p38 MAPK; AG490, an inhibitor of Janus activated kinase 2/3 (Jak2/3); GF109203X, an inhibitor of protein kinase C (PKC); and rapamycin, an inhibitor of mammalian target of rapamycin, were obtained from Calbiochem. RAW 264.7 cells were pretreated with these agents for 30 min prior to the addition of LPS, IFN-␥, or LPSϩIFN-␥.
RESULTS

Concurrent Suppression of NOS-2 and COX-2 Expressions in RAW 264.7 Cells by Sodium
Salicylate-It is well established that RAW 264.7 cells expressed both COX-2 and NOS-2 proteins in response to LPSϩIFN-␥ stimulation. To determine whether sodium salicylate at pharmacological concentrations suppresses COX-2 and NOS-2 expressions concurrently, we evaluated the effects of sodium salicylate on COX-2 and NOS-2 protein levels and promoter activities. Sodium salicylate suppressed COX-2 protein levels in serum-starved RAW 264.7 cells stimulated with LPSϩIFN-␥ for 4 h in a concentration-dependent manner with a maximal inhibition of ϳ50% at 10 Ϫ5 to 10 Ϫ4 M (Fig. 1a) . NOS-2 protein was detected after stimulation of RAW 264.7 cells with LPSϩIFN-␥ for 4 h and was suppressed by sodium salicylate (Fig. 1b) . Sodium salicylate at 10 with LPSϩINF-␥ for 4 h to a similar extent (Fig. 2) . We have observed in RAW 264.7 as well as in human fibroblasts that salicylate inhibited NOS-2 and COX-2 expressions only in serum-starved cells. When cells were cultured in the presence of 10% fetal bovine serum, salicylate did not inhibit NOS-2 or COX-2 protein levels stimulated by LPSϩIFN-␥ for 4 h (data not shown).
Inhibition by Salicylate of NOS-2 Promoter Activity at 4 h but Not at 24 h-In response to LPSϩIFN-␥ stimulation, COX-2
promoter activity peaked at 4 h and declined to near basal level at 8 h and thereafter (Fig. 3a) . In contrast, NOS-2 promoter activity increased progressively up to 24 h (Fig. 3b) . To determine the role of C/EBP element in NOS-2 promoter activity, we transfected cells with luciferase expression vector containing a C/EBP-mutated NOS-2 promoter fragment. The mutation of the C/EBP element resulted in the collapse of NOS-2 promoter activity at 4 h but not at 24 h (Fig. 4) , suggesting different transactivational pathways for 4 h versus 24-h stimulation by LPSϩIFN-␥. We next determined whether salicylate inhibited only the C/EBP-dependent NOS-2 expression. Sodium salicylate (10 Ϫ5 M) reduced NOS-2 promoter activity at 4 h by 50% but had no effect on NOS-2 promoter activity stimulated with LPSϩIFN-␥ for 24 h (Fig. 5) .
Suppression of C/EBP␤ Binding to NOS-2 and COX-2 Promoters by
Salicylate-Of several C/EBP␤ isoforms, only the 38-kDa C/EBP␤ was detectable in quiescent cells and its level was not altered by LPSϩIFN-␥ stimulation for 4 h (Fig. 6a) . C/EBP␤ binding to the NOS-2 promoter sequence was detected at basal state, which was enhanced by LPSϩIFN-␥ stimulation for 4 h (Fig. 6b) . Basal binding to COX-2 C/EBP sequence was not detected, but the binding was detectable at 4 h of stimulation (Fig. 6c) . Sodium salicylate at 10 Ϫ5 M did not alter C/EBP␤ protein levels (Fig. 6a ) but suppressed C/EBP␤ binding to NOS-2 and COX-2 promoter C/EBP sequences (Fig. 6, b and c) . By contrast, C/EBP␤ binding to NOS-2 sequence became undetectable after a 24-h treatment with LPSϩIFN-␥, which is correlated with a marked reduction of C/EBP␤ protein levels (Fig. 7) . Sodium salicylate had no effect on C/EBP␤ binding or protein level at 24 h of stimulation (Fig. 7) .
Salicylate Inhibited LPS-but Not IFN-␥-induced NOS-2 Protein Expression-LPS has been reported to induce COX-2 expression in RAW 264.7 cells at early time points (18) , but the kinetics of NOS-2 expression had not been analyzed. We determined the kinetics of NOS-2 expression induced by LPS and IFN-␥ individually. Under LPS stimulation, NOS-2 proteins were detected at 4 h and peaked at 12 h (Fig. 8) . In contrast, NOS-2 proteins were undetectable at 4 h after IFN-␥ stimulation became detectable at 8 h and peaked at 24 h (Fig. 8) . LPSϩIFN-␥ treatment resulted in synergistic stimulation of NOS-2 expression. Robust expression was detected at 4 h, peaked at 12 h, and declined significantly at 24 h. We next determined whether sodium salicylate inhibited NOS-2 protein expression stimulated by LPS, IFN-␥, or LPSϩIFN-␥ for 4 and 24 h. Salicylate (10 Ϫ5 M) inhibited LPS and LPSϩIFN-␥-induced NOS-2 protein levels at 4 h to a similar extent (Fig. 9) . It had no effect on IFN-␥-induced NOS-2 protein levels (Fig. 9) . Taken together, these results suggest that salicylate inhibited LPS-induced C/EBP␤ binding, thereby suppressing C/EBP␤-mediated COX-2 and NOS-2 expression.
NOS-2 and COX-2 Expression at 4 h Was Mediated by a Similar
Signaling Pathway-To gain insight into the signaling pathway via which salicylate blocks C/EBP␤ binding, we compared the signaling pathways through which NOS-2 and COX-2 expressions are stimulated by LPSϩIFN-␥ for 4 h. NOS-2 protein levels were significantly reduced by LY294002, SB203580, and AG490 (Fig. 10a) , consistent with the involvement of PI3K, p38 MAPK, and Jak2/3 in NOS-2 expression. COX-2 protein levels at 4 h were also inhibited by LY2942002, SB203580, and AG490 with an almost identical profile (Fig.  10b) . LY2942002 and SB203580 abrogated LPSϩIFN-␥-stimulated C/EBP␤ binding to the NOS-2 promoter sequence without changing the C/EBP␤ protein level (Fig. 11a) . Similarly, C/EBP␤ binding to COX-2 promoter sequence was blocked by these two inhibitors (Fig. 11b) . These results suggest a common signaling pathway through which NOS-2 and COX-2 promoter activities are stimulated by LPSϩIFN-␥ at 4 h.
In view of different kinetics of NOS-2 expression in response to LPS versus IFN-␥ stimulation, we were interested in knowing whether the signaling pathway for NOS-2 expression stimulated by LPSϩIFN-␥ for 4 h is attributable to LPS. We pretreated cells with LY294002 or PD98059 for 30 min followed by LPS, IFN-␥, or LPSϩIFN-␥ for 4 h. Cells were harvested, and NOS-2 proteins were determined. NOS-2 protein expression induced by LPS alone or LPSϩIFN-␥ was similarly inhibited by LY294002 but not by PD98059 (Fig. 12) . IFN-␥ did not induce detectable NOS-2 at 4 h, and pretreatment with these inhibitors did not alter its effect on NOS-2 protein expression (Fig.  12) . These results suggest that NOS-2 and COX-2 expressions after a 4 h stimulation by LPSϩIFN-␥ were contributed primarily by LPS via a signaling pathway involving several signaling molecules including PI3K. DISCUSSION Our findings indicate that salicylate at pharmacological concentrations is capable of suppressing NOS-2 and COX-2 expressions in RAW 264.7 macrophages by blocking C/EBP␤ binding to specific binding sites at the NOS-2 and COX-2 promoter regions. Our results further demonstrate that the concurrent NOS-2 and COX-2 expressions in response to LPSϩIFN-␥ stimulation for 4 h is attributable to the action of LPS, because IFN-␥ did not induce NOS-2 or COX-2 expression at this early time point. C/EBP␤ binding has been shown to be required for LPS-induced COX-2 transcriptional activation (18) . In this study, our results show that C/EBP␤ binding is also essential for NOS-2 transcriptional activation by LPS at 4 h. Salicylate was capable of suppressing C/EBP␤ binding to the promoters of both genes. These results suggest that salicylate suppresses NOS-2 and COX-2 transcription by a common C/EBP␤-dependent mechanism. We have previously demonstrated that COX-2 stimulation by phorbol 12-myristate 13-acetate and interleukin-1␤ (13) in human fibroblasts also requires C/EBP␤ binding, and salicylate exerts a similar effect on blocking C/EBP␤ binding, thereby suppressing COX-2 transactivation. In contrast, salicylate does not suppress COX-2 stimulation by tumor necrosis factor ␣ whose stimulation does not require C/EBP␤ binding. Taken together, these results indicate that C/EBP␤ binding is a key target of salicylate action. It may be predicted that salicylate is capable of suppressing an array of C/EBP␤-dependent genes. This action of salicylate could explain the therapeutic effects of aspirin on diverse human diseases.
The mechanism by which salicylate blocks C/EBP␤ binding has not been characterized. As C/EBP␤ binding depends on phosphorylation, it is probable that salicylate disrupts C/EBP␤ phosphorylation by inhibiting the kinase activity. The exact kinase that phosphorylates C/EBP␤ and enhances its binding and transactivation properties remains to be identified. Several kinases including p90 ribosomal S6 kinase, calmodulin-dependent kinase, MAPK, PKC, and PKA have been shown to phosphorylate C/EBP␤ at distinct tyrosine or serine/threonine residues (19 -22) . It is unclear whether all of the phosphorylation sites are required for C/EBP␤ binding, nor is it clear whether all the kinases are activated by each stimulus. It is possible that each type of agonists may activate several kinases that act in concert to promoter C/EBP␤ binding. Salicylate may block one of the kinase activity, thereby weakening the C/EBP␤ binding. Our results suggest that neither PKC nor p42/p44 MAPK is a target of salicylate, because the inhibition of PKC or MAPK did not alter C/EBP␤ binding. Work is in progress to determine whether ribosomal S6 kinase, calmodulin-dependent kinase, or PKA is the target of salicylate inhibition.
Our results demonstrate different kinetics of NOS-2 and COX-2 promoter activation by LPSϩIFN-␥. COX-2 expression by the combined stimuli follows a time course that is characteristic of COX-2 induction by other agonists including LPS. Its promoter activity stimulated by LPS or LPSϩIFN-␥ peaked at 4 h and declined rapidly thereafter. The addition of IFN-␥ does not potentiate the stimulatory effect of LPS nor does it prolong the time course of COX-2 stimulation. In contrast, NOS-2 expression by the combined stimuli has a prolonged time course, which is contributed primarily by IFN-␥. Our time course of NOS-2 expression by the combined stimuli is consistent with the reported data (23, 24) . However, the time course of NOS-2 expression under the stimulation of LPS or IFN-␥ had not been extensively investigated. Our results show a different time course of NOS-2 expression stimulated by these two agonists. LPS induced an early and short-term NOS-2 expression resembling the time course of COX-2 expression, whereas IFN-␥ stimulated NOS-2 expression with a late onset and a prolonged time course. This kinetic difference is attributable to distinct receptor-mediated signaling pathways used by these two agonists to induce the binding of different transactivators to their respective regulatory elements on the NOS-2 promoter. The synergistic action of LPSϩIFN-␥ could be explained by a complementary time course of stimulation, recruitment of multiple transactivators and coactivators to the promoter, and dynamic switch of transactivator binding over time caused by these two agonists. These processes are complex and possibly coordinately regulated. The results from this study provide direct evidence for a time-dependent change in C/EBP␤ binding that correlates with the early short-term NOS-2 expression. C/EBP␤ binding is absolutely required for NOS-2 expression at 4 h but not at 24 h. The binding of other transactivators, notably NFB and interferon regulatory factor-1, is probably responsible for the late onset and sustained NOS-2 expression stimulated by LPSϩIFN-␥. It is interesting to note that C/EBP␤ proteins are degraded by prolonged LPSϩIFN-␥ stimulation, which results in the switch-off of the C/EBP␤ binding. It will be important to determine the time course of binding of other functionally important transactivators in response to stimulation by LPS, IFN-␥, or LPSϩIFN-␥ and evaluate the effect of salicylate on the binding of these transactivators at different time points.
NOS-2 transcriptional activation in response to stimulation by LPSϩIFN-␥ at 4 and 24 h may be mediated through distinct signaling pathways. Our results indicate that at 4 h of stimulation, promoter activation is mediated via a pathway involving PI3K, p38 MAPK, and Jak2/3. On the other hand, our data 2 also reveal that NOS-2 transcriptional activation by LPSϩIFN-␥ for 24 h was inhibited by GF109203X and rapamycin and augmented by LY294002, SB203580, AG490, and PD98059, suggesting that NOS-2 expression at 24 h is mediated via a signaling pathway involving PKC and mammalian target of rapamycin and negatively regulated by PI3K, p38 2 K. Cieslik, Y. Zhu, and K. K. Wu, unpublished data. MAPK, Jak2/3, and MEK1/2. Only a small number of reports address signaling pathways for LPSϩIFN-␥-induced NOS-2 expression in RAW 264.7 cells. These reports provide information on signaling pathways for NOS-2 expression at 4 -6 or 20 -24 h but did not provide kinetic data. For example, Salh et al. (25) report the inhibition of NOS-2 expression at 6 h by LY294002, whereas Diaz-Guerra et al. (26) and Chen et al. (27) report the involvement of PKC in NOS-2 expression at 24 h. Diaz-Guerra et al. (28) report that NO production stimulated by LPSϩIFN-␥ for 24 h was augmented by LY294002. These results are consistent with our findings that PI3K mediates NOS-2 expression at 4 -6 h and negatively regulates its expression at 24 h. Taken together, these results support the notion that NOS-2 expression stimulated by LPSϩIFN-␥ comprises two distinct phases that are signaled by different pathways: 1) an early phase of expression, which is signaled through PI3K, p38 MAPK, and Jak 2/3; and 2) a late phase of expression, which is signaled via PKC and mammalian target of rapamycin. In this study, we have characterized considerably the early phase of expression. The early phase NOS-2 expression resembles the expression of an immediate early gene such as COX-2. Its signaling pathway leads to C/EBP␤ binding and C/EBP␤-mediated transcriptional activation. We have demonstrated that salicylate is capable of suppressing the early phase NOS-2 expression by blocking C/EBP␤ binding, and this inhibitory process also resembles its suppression of COX-2 transcriptional activation. In contrast, the late phase NOS-2 expression has not been characterized. Its signaling pathways appear to be complex, comprising positive and negative signaling pathways. The role of the negative signaling pathway in controlling the late phase NOS-2 expression is unclear. It is also unclear which transcriptional activators are activated through the positive signaling pathway and which transcription factors are controlled by the negative pathway. Our results have excluded the involvement of C/EBP␤ in the late phase NOS-2 transcriptional activation. It is possible that NFB and interferon regulatory factor-1 are the key transactivators for the late phase NOS-2 expression. Work is now in progress to characterize the signaling and transcriptional pathways for the late phase NOS-2 expression and the pharmacological control of its expression.
